Literature DB >> 7980629

Expression and function of multidrug resistance P-glycoprotein in a cultured natural killer cell-rich population revealed by MRK16 monoclonal antibody and AHC-52.

Y Kobayashi1, T Yamashiro, H Nagatake, T Yamamoto, N Watanabe, H Tanaka, K Shigenobu, T Tsuruo.   

Abstract

Natural killer (NK) cells have been reported recently to be the highest in expressing multidrug resistance (MDR) P-glycoprotein among normal mature lymphoid cells. Using a cultured NK cell-rich population, we have examined the expression and function of P-glycoprotein, in particular its role in NK cell-mediated cytotoxicity, by employing two MDR-reversing agents (nicardipine and AHC-52, a nicardipine analog almost devoid of calcium channel blocking activity) and monoclonal antibody against P-glycoprotein (MRK-16). The expression of P-glycoprotein was detected by flow cytometry and polymerase chain reaction of reverse transcribed mRNA. P-glycoprotein was functional in terms of rhodamine dye excretion and its susceptibility to the MDR-reversing agents. Since the concentration of nicardipine required for 50% inhibition (IC50) of rhodamine dye excretion (2 microM) was close to that of AHC-52 (5 microM), it was suggested that their inhibitory effects were not due to calcium channel blocking activity, and that ACH-52 is a selective inhibitor for P-glycoprotein. The IC50 of nicardipine for NK cell-mediated cytotoxicity (33 microM) was also close to that of AHC-52 (26 microM), indicating that P-glycoprotein is involved in NK cell-mediated cytotoxicity. In support of this, MRK16 inhibited NK cell-mediated cytotoxicity in a concentration-dependent manner. Both binding of target cells to NK cells and post-binding events were affected by AHC-52, suggesting that P-glycoprotein is involved in several steps in NK cell-mediated cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7980629     DOI: 10.1016/0006-2952(94)90209-7

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  6 in total

1.  Conformational analysis of human ATP-binding cassette transporter ABCB1 in lipid nanodiscs and inhibition by the antibodies MRK16 and UIC2.

Authors:  Tasha K Ritchie; Hyewon Kwon; William M Atkins
Journal:  J Biol Chem       Date:  2011-09-21       Impact factor: 5.157

2.  P-glycoprotein and alloimmune T-cell activation.

Authors:  Shona S Pendse; David M Briscoe; Markus H Frank
Journal:  Clin Appl Immunol Rev       Date:  2003-07

3.  A novel in vivo regulatory role of P-glycoprotein in alloimmunity.

Authors:  Atsushi Izawa; Tobias Schatton; Natasha Y Frank; Takuya Ueno; Kazuhiro Yamaura; Shona S Pendse; Armen Margaryan; Martin Grimm; Martin Gasser; Ana Maria Waaga-Gasser; Mohamed H Sayegh; Markus H Frank
Journal:  Biochem Biophys Res Commun       Date:  2010-03-15       Impact factor: 3.575

4.  Activation of human peripheral blood T cells does not lead to increased P-glycoprotein expression.

Authors:  X Y Mu; M P Gosland; M M Bartik; J Schimmelpfennig; N E Kay
Journal:  J Clin Immunol       Date:  1999-07       Impact factor: 8.317

5.  P-glycoprotein-mediated multidrug resistance and lymphokine-activated killer cell susceptibility in ovarian carcinoma.

Authors:  B Savas; S P Cole; T Tsuruo; H F Pross
Journal:  J Clin Immunol       Date:  1996-11       Impact factor: 8.317

Review 6.  Natural Products as Alternative Choices for P-Glycoprotein (P-gp) Inhibition.

Authors:  Saikat Dewanjee; Tarun K Dua; Niloy Bhattacharjee; Anup Das; Moumita Gangopadhyay; Ritu Khanra; Swarnalata Joardar; Muhammad Riaz; Vincenzo De Feo; Muhammad Zia-Ul-Haq
Journal:  Molecules       Date:  2017-05-25       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.